| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-09-16 | Xultophy®/IDegLira (combination of insulin degludec (Tresiba®) and liraglutide (Victoza®)) | type 2 diabetes | 3b | Novo Nordisk (Denmark) | Metabolic diseases |
| 2016-09-16 | IMM-101 (heat killed whole cell mycobacterium obuense) | advanced pancreatic cancer | 2 | Immodulon Therapeutics (UK) | Cancer - Oncology |
| 2016-09-15 | GSK3326595 | solid tumors, non-Hodgkin's lymphoma | 1 | GSK (UK) | Cancer - Oncology |
| 2016-09-15 | ertugliflozin | type 2 diabetes | 3 | Merck&Co (USA - NJ) Pfizer (USA - NY) | Metabolic diseases |
| 2016-09-15 | ABO-102 (SC AAV-SGSH) | mucopolysaccharidosis type IIIA (Sanfilippo B syndrome) | preclinical | Abeona Therapeutics (USA - NY) | Rare diseases - Genetic diseases |
| 2016-09-15 | SFX-01 | multiple sclerosis | preclinical | Evgen Pharma (UK) | Neurodegenerative diseases |
| 2016-09-15 | familial chylomicronemia syndrome | Akcea Therapeutics (USA - CA), a subsidiary of Ionis Pharmaceuticals (USA - CA) | Rare diseases - Genetic diseases | ||
| 2016-09-15 | benralizumab | asthma | 3 | AstraZeneca (UK) | Allergic diseases – Inflammatory diseases – Respiratory diseases |
| 2016-09-15 | Zinbryta™ (Daclizumab High-Yield Process - DAC HYP) | relapsing-remitting multiple sclerosis | 3 | BiogenIdec (USA - MA) AbbVie (USA - IL) | Neurodegenerative diseases |
| 2016-09-15 | ZW25 - anti-HER2 bispecific antibody | HER2-expressing tumors | 1 | Zymeworks (Canada) | Cancer - Oncology |
| 2016-09-14 | GBT440 | hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis | preclinical | Global Blood Therapeutics (USA - CA) | Lung diseases - Respiratory diseases - Rare diseases |
| 2016-09-14 | binimetinib, encorafenib and cetuximab | metastatic colorectal cancer (mCRC) | 3 | Array BioPharma (USA - CO) Pierre Fabre (France) Merck KGaA (Germany) | Cancer - Oncology |
| 2016-09-14 | MD1003 (high doses of pharmaceutical-grade biotin) | adrenoleukodystrophy | preclinical | Medday (France) | Rare diseases - Genetic diseases |
| 2016-09-14 | GMI-1271 | multiple myeloma | 1 | GlycoMimetics (USA - Md) | Cancer - Oncology |
| 2016-09-13 | NeuVax™ (nelipepimut-S) | ovarian cancer, pancreatic cancer | preclinical | Galena Biopharma (USA - OR) | Cancer - Oncology |
| 2016-09-13 | inecalcitol | acute myeloid leukemia (AML) | 2 | Hybrigenics (France) | Cancer - Oncology |
| 2016-09-12 | bacteriophage cocktail against Clostridium difficile | Clostridium difficile infections | preclinical | AmpliPhi BioSciences (USA - VA) Leicester University (UK) | Infectious diseases |
| 2016-09-12 | Generx® [Ad5FGF-4] gene therapy | myocardial ischemia and refractory angina due to advanced coronary artery disease | 3 | Angionetics (USA - CA) Huapont Life Sciences Affiliate (China) | Cardiovascular diseases |
| 2016-09-12 | Livatag® (doxorubicin Transdrug®) | hepatocellular carcinoma | preclinical | Onxeo (France) | Cancer - Oncology |
| 2016-09-09 | Zalmoxis® (investigational cell therapy product TK) | high-risk leukemia | 3 | MolMed (Italy) | Cancer - Oncology |
